Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
Status:
Not yet recruiting
Trial end date:
2024-09-02
Target enrollment:
Participant gender:
Summary
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against
refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted
CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another
strategy to treat refractory lymphoma, even after relapse following cluster of
differentiation antigen 19 (CD19) targeting CAR-T treatment.
This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF
CAR-T cells against relapsed non-Hodgkin lymphoma using a single lymphodepletion regimen and
using a BAFF CAR-T cell manufacturing process.